Die Klinik für Thoraxchirurgie wird in ihrer intensiven Forschungstätigkeit von verschiedenen nationalen und internationalen Stiftungen sowie Institutionen mit einer finanziellen Zuwendung unterstützt. Folgende medizinischen Mitarbeitende erhielten für ihre Projekte einen Grant und sind namentlich im Annual Report erwähnt.
| Quelle | Projekttitel | Projektleiter |
|---|---|---|
| Schweizerischer Nationalfonds | EMERGE – Unraveling plEural Mesothelioma hEteRoGeneity aiming for pErsonalized treatment | Schmitt-Opitz, Isabelle; Kirschner, Michaela, Meerang Mayura |
| Schweizerischer Nationalfonds | Randomised controlled trial comparing maintenance with the addition of local ablative treatment of patients with advanced stage IV non-small cell lung cancer – salVage-Trial | Schmitt-Opitz, Isabelle; Guckenberger, Matthias; Curioni-Fontecedro, Alessandra; Held, Ulrike |
| Quelle | Projekttitel | Projektleiter |
|---|---|---|
| ETOP European Thoracic Oncology Platform | ETOP 2-11/M027911 BELIEF-phase II, open label trial with erlotinib/bevacizumab in advanced NSCLC EGFR mut+ | Schmitt-Opitz, Isabelle |
| Johnson & Johnson AG | J&J Ethicon Endo Surgery – Lungenkresoperation beim Emphysem und Mobidität der LVRS | Schmitt-Opitz, Isabelle |
| Krebsforschung Schweiz | Mesoscape 001 – pS6: construction of a multi-institutional European tissue bank (KFS-3626-02-2015 | Schmitt-Opitz, Isabelle |
| SUVA | Klinische Phase II Studie zur Evaluation intrakavitärer Chemotherapie mit Cisplatin-Fibrin nach Mesotheliom-Resektion | Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | Multi-omics profiling for identification of novel circulating biomarkers for malignant pleural mesothelioma | Schmitt-Opitz, Isabelle, M.Meerang, M.Kirschner |
| University Hospital Zurich Foundation (Iten-Kohaut Stiftung) | Tracking down Non-Small Cell Lung Cancer: Targeted Sequencing of Exosomes from Primary Tumor Cell Cultures – a Proof of Principles for the TrackTHORAX Project | Schmitt-Opitz, Isabelle, Raphael Werner |
| Baugarten Stiftung (via UZH Foundation) | Surgical in comparison to bronchoscopic lung volume reduction in patients with advanced emphysema: a multi-center randomized controlled trial |
Schmitt-Opitz, Isabelle |
| ICON Clinical Research Limited/BMS | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung | Schmitt-Opitz, Isabelle |
| Schweizerischer Nationalfonds SNF | Improving Mesothelioma Patients Outcomes by Early Non-Invasive Diagnosis | Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | Immune cell profiling of oligo-metastatic non-small cell lung cancer patients: Comparison of primary tumor with different sites of metastasis for impact on prognosis and immunotherapy | Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | Innovation in Management of Small Pulmonary Nodules | Schmitt-Opitz, Isabelle; Frauenfelder Thomas |
| SAKF Stiftung für angewandte Krebsforschung | Establishment and long-term expansion of primary non-small cell lung cancer organoids: setting the foundation for an individualized precision medicine using ex-vivo cancer models |
Schmitt-Opitz, Isabelle; Jungraithmayr, Wolfgang; Kirschner, Michaela; Jae Hwi, Jang; Raphael Werner |
| LUNGE ZÜRICH | Surglcal compared to broNChoscopic lung volumE Reduction in patients with severe Emphysema: a multi-center randomized controlled trial „SINCERE“ |
Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | MikroRNAs in malignen Pleuramesotheliom – Regulatoren der Therapieresistenz und mögliche Biomarker. | Kirschner, Michaela |
| Stiftung Krebsforschung Schweiz | A new therapeutic concept against lung cancer by Inhibition of CD26/DPP4 | Jungraithmayr, Wolfgang |
| Krebsliga Zürich | Targeting lung cancer by CD26/DPP4 inhibition in combination with anti-PD-L1 antibody | Jungraithmayr, Wolfgang |
| SAKF Stiftung für angewandte Krebsforschung | Targeting lung cancer by CD26/DPP4 inhibition in combination with an immune checkpoint inhibitor | Jungraithmayr, Wolfgang |
| Swiss Lung Foundation | Ein Kleintiermodell zur Rekonditionierung von marginalen Spenderlungen mit dem ex-vivo Lungenperfusions-System unter Verwendung einer neuen Perfluorkarbon-Emulsion vor Transplantation. | Inci, Ilhan |
| Foundation A.P.Naef, Prof. hon. Ludwig K. von Segesser | Extra-corporeal lung perfusion | Inci, Ilhan |
| Jubiläumsstiftung der LLGR | Inhibition of ischemia-reperfusion injury using ATP sensitive potassium channel modulators in ex vivo lung perfusion system in lung transplantation | Inci, Ilhan |
| CytoSorbents Europe GmbH | The effect of cytokine removal during ex vivo lung perfusion on post-transplant graft function | Inci, Ilhan |
| CytoSorbents Europe GmbH | Cytosorb Transplantation | Inci, Ilhan |
| Theodor und Ida Herzog-Egli-Stiftung | Effekt von NAD+ (Nicotinamidadenindinukleotid) auf den Ischämie- Reperfusionschaden sowie die akute Organabstossung nach Lungentransplantation |
Inci, Ilhan |
| SAKF Stiftung für angewandte Krebsforschung | Stiftung für angewandte Krebsforschung: Biomarkers with enzymatic activities for improved risk stratification of lung cancer patients | Hillinger, Sven |
| Krebsliga Zürich | Sonic hedgehog signaling in malignant pleural mesothelioma | Felley-Bosco, Emanuela |
| Schweizerischer Nationalfonds SNF | RNA editing in mesothelioma: a new therapeutic target | Felley-Bosco, Emanuela |
| Walter Bruckerhoff Stiftung | The Supraspliceosome, a multi-task RNA processing machine, as novel target for diagnosis and treatement of thoracic cancers | Felley-Bosco, Emanuela |
| SAKF Stiftung für Angewandte Krebsforschung | RNA editing in mesothelioma: a new therapeutic target? | Felley-Bosco, Emanuela |
| Quelle | Projekttitel | Projektleiter |
| ETOP European Thoracic Oncology Platform | ETOP 2-11/M027911 BELIEF-phase II, open label trial with erlotinib/bevacizumab in advanced NSCLC EGFR mut+ | Schmitt-Opitz, Isabelle |
|---|---|---|
| Johnson & Johnson AG | J&J Ethicon Endo Surgery – Lungenkresoperation beim Emphysem und Mobidität der LVRS | Schmitt-Opitz, Isabelle |
| Krebsforschung Schweiz | Mesoscape 001 – pS6: construction of a multi-institutional European tissue bank (KFS-3626-02-2015 | Schmitt-Opitz, Isabelle |
| SUVA | Klinische Phase II Studie zur Evaluation intrakavitärer Chemotherapie mit Cisplatin-Fibrin nach Mesotheliom-Resektion | Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | Multi-omics profiling for identification of novel circulating biomarkers for malignant pleural mesothelioma | Schmitt-Opitz, Isabelle, M.Meerang, M.Kirschner |
| Kurt und Senta Herrmann Stiftung | Tracking down Non-Small Cell Lung Cancer: Targeted Sequencing of Exosomes from Primary Tumor Cell Cultures – a Proof of Principles for the TrackTHORAX Project | Schmitt-Opitz, Isabelle, Raphael Werner |
| University Hospital Zurich Foundation (Iten-Kohaut Stiftung) | Tracking down Non-Small Cell Lung Cancer: Targeted Sequencing of Exosomes from Primary Tumor Cell Cultures – a Proof of Principles for the TrackTHORAX Project | Schmitt-Opitz, Isabelle, Raphael Werner |
| Baugarten Stiftung (via UZH Foundation) | Surgical in comparison to bronchoscopic lung volume reduction in patients with advanced emphysema: a multi-center randomized controlled trial |
Schmitt-Opitz, Isabelle |
| ICON Clinical Research Limited/BMS | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung | Schmitt-Opitz, Isabelle |
| Schweizerischer Nationalfonds SNF | Improving Mesothelioma Patients Outcomes by Early Non-Invasive Diagnosis | Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | Immune cell profiling of oligo-metastatic non-small cell lung cancer patients: Comparison of primary tumor with different sites of metastasis for impact on prognosis and immunotherapy | Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | Innovation in Management of Small Pulmonary Nodules | Schmitt-Opitz, Isabelle; Frauenfelder Thomas |
| LUNGE ZÜRICH | Surglcal compared to broNChoscopic lung volumE Reduction in patients with severe Emphysema: a multi-center randomized controlled trial „SINCERE“ |
Schmitt-Opitz, Isabelle |
| SAKF Stiftung für angewandte Krebsforschung | The role of microRNAs in malignant pleural mesothelioma progression and therapy resistance | Kirschner, Michaela |
| SAKF Stiftung für angewandte Krebsforschung | MikroRNAs in malignen Pleuramesotheliom – Regulatoren der Therapieresistenz und mögliche Biomarker. | Kirschner, Michaela |
| Stiftung Krebsforschung Schweiz | A new therapeutic concept against lung cancer by Inhibition of CD26/DPP4 | Jungraithmayr, Wolfgang |
| Krebsliga Zürich | Targeting lung cancer by CD26/DPP4 inhibition in combination with anti-PD-L1 antibody | Jungraithmayr, Wolfgang |
| SAKF Stiftung für angewandte Krebsforschung | Targeting lung cancer by CD26/DPP4 inhibition in combination with an immune checkpoint inhibitor | Jungraithmayr, Wolfgang |
| Swiss Lung Foundation | Ein Kleintiermodell zur Rekonditionierung von marginalen Spenderlungen mit dem ex-vivo Lungenperfusions-System unter Verwendung einer neuen Perfluorkarbon-Emulsion vor Transplantation. | Inci, Ilhan |
| Foundation A.P.Naef, Prof. hon. Ludwig K. von Segesser | Extra-corporeal lung perfusion | Inci, Ilhan |
| Jubiläumsstiftung der LLGR | Inhibition of ischemia-reperfusion injury using ATP sensitive potassium channel modulators in ex vivo lung perfusion system in lung transplantation | Inci, Ilhan |
| Schweizerischer Nationalfonds SNF | Reconditioning of marginal donor lung in ex vivo lung perfusion system using perfluorocarbon based oxygen carrier. | Inci, Ilhan |
| CytoSorbents Europe GmbH | The effect of cytokine removal during ex vivo lung perfusion on post-transplant graft function | Inci, Ilhan |
| Swiss Lung Foundation | Bau einer Unterdruckkammer für zu transplantierende Lungen | Inci, Ilhan |
| Theodor und Ida Herzog-Egli-Stiftung | Effekt von NAD+ (Nicotinamidadenindinukleotid) auf den Ischämie- Reperfusionschaden sowie die akute Organabstossung nach Lungentransplantation |
Inci, Ilhan |
| SAKF Stiftung für angewandte Krebsforschung | Stiftung für angewandte Krebsforschung: Biomarkers with enzymatic activities for improved risk stratification of lung cancer patients | Hillinger, Sven |
| SAKF Stiftung für angewandte Krebsforschung | Innovative Abklärungsmöglichkeiten des kleinen pulmonalen Rundherdes | Hillinger, Sven |
| Krebsliga Zürich | Sonic hedgehog signaling in malignant pleural mesothelioma | Felley-Bosco, Emanuela |
| Schweizerischer Nationalfonds SNF | RNA editing in mesothelioma: a new therapeutic target | Felley-Bosco, Emanuela |
| Walter Bruckerhoff Stiftung | The Supraspliceosome, a multi-task RNA processing machine, as novel target for diagnosis and treatement of thoracic cancers | Felley-Bosco, Emanuela |
| SAKF Stiftung für Angewandte Krebsforschung | RNA editing in mesothelioma: a new therapeutic target? | Felley-Bosco, Emanuela |
|
Quelle |
Projekttitel |
Projektleiter |
| Walter Bruckerhoff Stiftung |
The Supraspliceosome, a multi-task RNA processing machine, as novel target for diagnosis and treatment of thoracic cancer
|
Emanuela Felley-Bosco
|
|---|---|---|
| Stiftung für Angewandte Krebsforschung |
RNA editing in mesothelioma: a new therapeutic target
|
Emanuela Felley-Bosco
|
|
Schweizer Nationalfond
|
Improving Mesothelioma Patients Outcomes by Early Non-Invasive Diagnosis
|
I. Opitz
|
|
Iten-Kohaut Stiftung
|
Tracking down Non-Small Cell Lung Cancer: on the road to personalized medicine for Lung Cancer (TrackTHORAX)
|
I. Opitz
|
|
Stiftung für Angewandte Krebsforschung
|
Multi-omics profiling for identification of novel circulating biomarkers for malignant pleural mesothelioma
|
I. Opitz, M. Meerang, M. Kirschner
|
|
Stiftung für Angewandte Krebsforschung
|
Proteogenomic biomarker analysis of malignant pleural mesothelioma
|
P. Wild, I. Opitz
|
|
Polianthes Stiftung
|
Next Generation Sequencing of Malignant Pleural Mesothelioma for Therapy Response Prediction
|
P. Wild, I. Opitz
|
|
Krebsliga Schweiz
|
Mesoscape 001-pS6: Construction of a multi-institutional European Tissuebank
|
I. Opitz
|
|
Kurt und Senta Hermann Stiftung
|
Tracking down NSCLC: targeted sequencing of exosomes from primary tumor cell cultures – a proof of principle for the TrackTHORAX Project
|
R. Werner, I. Opitz
|
|
Stiftung für Angewandte Krebsforschung
|
The role of microRNAs in malignant pleural mesothelioma progression and therapy resistance
|
M. Kirschner, I. Opitz
|
|
Kantonalzürcherische Krebskommission
|
The role of microRNAs in malignant pleural mesothelioma progression and resistance to chemo- and immunotherapy
|
M. Kirschner
|
|
Krebsliga Zürich |
Targeting Lung Cancer by CD26/DPP4-inhibition in combination with anti-PD-L1 antibody
|
W. Jungraithmayr
|
| Quelle | Projekttitel | Projektleiter |
|
Schweizer Nationalfond
|
Malignant Pleural Mesothelioma – an integrative approach for better outcomeImproving Mesothelioma Patients Outcomes by Early Non-Invasive Diagnosis
|
I. Opitz
|
|---|---|---|
|
Stiftung für Angewandte Krebsforschung
|
Multi-omics profiling for identification of novel circulating biomarkers for malignant pleural mesothelioma
|
I. Opitz, M. Meerang, M. Kirschner
|
|
Quelle |
Projekttitel |
Projektleiter |
|
Schweizer Nationalfond
|
Malignant Pleural Mesothelioma – an integrative approach for better outcome
|
I. Opitz
|
|---|---|---|
|
Stiftung für Angewandte Krebsforschung
|
Multi-omics profiling for identification of novel circulating biomarkers for malignant pleural mesothelioma
|
I. Opitz, M. Meerang, M. Kirschner
|
|
Stiftung für Angewandte Krebsforschung
|
Proteogenomic biomarker analysis of malignant pleural mesothelioma
|
P. Wild, I. Opitz
|
|
Polianthes Stiftung
|
Next Generation Sequencing of Malignant Pleural Mesothelioma for Therapy Response Prediction
|
P. Wild, I. Opitz
|
|
Verein Lunge Zürich
|
MicroRNAs as prognostic and predictive tumour markers assisting the selection of patients with malignant pleural mesothelioma for multimodality treatment
|
I. Opitz, M. Kirschner
|
|
Krebsliga Schweiz
|
Mesoscape 001-pS6: Construction of a multi-institutional European Tissuebank
|
I. Opitz
|
|
Stiftung für Angewandte Krebsforschung
|
Proteogenomic biomarker analysis of malignant pleural mesothelioma
|
I. Opitz, M. Meerang, M. Kirschner
|
|
Swiss National Science Foundation Sinergia grant
|
From asbestos exposure to cancer: a systemic approach to detect loss of homeostatic control in the mesothelial environment
|
E. Felley-Bosco
|
|
Walter Bruckerhoff Stiftung
|
Targeting epigenetic deregulation
|
E. Felley-Bosco
|
|
Polianthes Stiftung
|
Mechanisms underlying development of resistance and progression to mesenchymal phenotype in mesothelioma
|
E. Felley-Bosco
|
|
Schweizer Nationalfond
|
Reconditioning of marginal donor lung in ex vivo lung perfusion system using perfluorocarbon based oxygen carrier
|
I. Inci
|
|
A. P. Naef Stiftung
|
Inhibition of ischemia reperfusion injury using ATP sensitive potassium channel modulators in ex vivo lung perfusion system in lung transplantation
|
I. Inci
|
|
Zürcher Lungenstiftung |
A small animal model for reconditioning marginal donor lung in ex vivo lung perfusion system using an advanced perfluorocarbon emulsion before transplantation
|
I. Inci
|
|
Lungenliga Graubünden
|
Inhibition of ischemia-reperfusion injury using ATP sensitive potassium
channel modulators in ex vivo lung perfusion system in lung transplantation |
I. Inci
|
|
Sophien Stiftung
|
A new therapeutic concet against lung cancer by inhibition of CD26/DPP4
|
W. Jungraithmayr
|
|
„Clinical Scientist“, Medizinische Hochschule Brandenburg.
|
Targeting lung cancer by CD26-inhibition
|
W. Jungraithmayr
|
|
Quelle |
Projekttitel |
Projektleiter |
|
Zürcher Krebsliga
|
Prognostic Marker for MPM
|
I. Opitz
|
|---|---|---|
|
SNF Overhead
|
|
I. Opitz
|
|
Stiftung Becon
|
Gewebe- und Datenbank für das MPM – ein paneuropäisches Projekt
|
I. Opitz
|
|
Vontobel Stiftung
|
MikroRNAs als prognostische und prädiktive Tumormarker für die multimodale Behandlung des malignen Pleuramesothelioms
|
I. Opitz
|
|
Lunge Zürich
|
MicroRNAs as prognostic and predictive tumour markers assisting the selection of patients with malignant pleural mesothelioma for multimodality treatment
|
I. Opitz
|
|
SNF Professorship
|
MPM – an integral approach for better outcome
|
I. Opitz
|
|
Krebsforschung Schweiz
|
Mesoscape 001-pS6: Construction of a multi-institutional European Tissuebank
|
I. Opitz
|
|
Polianthes Foundation
|
Comprehensive Investigation of Predictive Biomarkers for Chemotherapy Response and Novel Drug Targets in Patients with MPM by Next Generation Sequencing
|
I. Opitz
|
|
Stiftung für Angewandte Krebsforschung
|
Multi-omics profiling for identification of novel circulating biomarkers for malignant pleural mesothelioma
|
I. Opitz
|
|
Swiss National ScienceFoundation Sinergia grant
|
From asbestos exposure to cancer: a systemic approach to detect loss of homeostatic control in the mesothelial environment
|
E. Felley-Bosco
|
|
Walter Bruckerhoff Stiftung
|
Targeting epigenetic deregulation
|
E. Felley-Bosco
|
|
Polianthes Foundation
|
Mechanisms underlying development of resistance and progression to mesenchymal phenotype in mesothelioma
|
E. Felley-Bosco
|
|
Innovationspool
|
Implementierung der „Synapse 3D®“ Software von Fujifilm zur Planung undSimulation von (minimal-invasiven) anatomischen Lungenresektionen, Lungenvolumenreduktionschirurgie und minimal-invasiven Zugängen
|
C. Caviezel
|
|
Hartmann Müller Stiftung
|
The role of cytokine filtration during ex vivo lung perfusion
|
I. Inci
|
|
Hermann Klaus Stiftung
|
Ex vivo reconditioning of donor lungs with Trimetazidine after prolonged cold ischemia
|
I. Inci
|
|
Lungen Liga Zurich
|
The effect of lung volume reduction surgery on outcome after lung transplantation in patients with emphysema
|
I. Inci
|
|
Innovationspool
|
Assessment and reconditioning of donor lungs with ex vivo lung perfusion system
|
I. Inci
|
|
Schweizerischer Nationalfonds
|
Suppression of lung tumor growth by CD26 /DPP4-inhibition
|
W. Jungraithmayr
|
|
Helene Bieber Fonds
|
The CD26-costimutatory pathway is critical for Th17-mediated lung transplant improvement
|
W. Jungraithmayr
|
|
Hartmann-Müller Stiftung
|
The protective effect of local anesthetics on primary graft dysfunction after experimental lung transplantation
|
W. Jungraithmayr
|
|
Kurt und Senta Herrmann- Stiftung
|
Blockade of CD26/DPP4 – co-stimulation to improve lung transplant survival
|
W. Jungraithmayr
|
|
Stiftung für wissenschaftliche
Forschung |
Ein neues Therapiekonzept zur Bekämpfung des Lungenkarzinoms durch
Hemmung der CD26/DPP4 |
W. Jungraithmayr
|
|
Forschungskredit, University Zurich |
The protective role of CD26/DPP4-inhibition in lung transplantation – a preclinical study
|
W. Jungraithmayr
|
|
Assistant Professorship,
University Zurich |
Lungentransplantation
|
W. Jungraithmayr
|
|
Development program
“Filling the Gap” |
The protective role of CD26/DPP4-inhibition in lung transplantation – a preclinical study
|
W. Jungraithmayr
|
|
Hermann Klaus-Stiftung,
University Zurich |
A new therapeutic concept against lung cancer through inhibition of CD26/ DPP4
|
W. Jungraithmayr
|
|
Stiftung für Krebsbekämpfung, University Zurich
|
Ein neues Therapiekonzept zur Bekämpfung des Lungenkarzinoms durch Hemmung der CD26/DPP4
|
W. Jungraithmayr
|
|
Stiftung für Angewandte Krebsforschung
|
Biomarkers with enzymatic activities for improved risk stratification of lung cancer patients
|
S. Hillinger
|
|
Quelle |
Projekttitel |
Projektleiter |
|
Swiss National Science Foundation
|
From asbestos-exposure to cancer: a systemic approach to detect loss of homeostatic control in the mesothelial environment |
E. Felley-Bosco |
|---|---|---|
|
Baumgarten Stiftung |
Preclinical Malignant Pleural Mesothelioma models to accelerate clinical research on targeted therapy |
E. Felley-Bosco |
|
Walter Bruckerhoff Stiftung |
Targeting epigenetic deregulation |
E. Felley-Bosco |
|
Polianthes Foundation |
Overcoming development of resistance and progression to mesenchymal phenotype in mesothelioma |
E. Felley-Bosco |
|
Polianthes Foundation |
Comprehensive investigation of predictive biomarkers for chemotherapy response and novel drug targets in patients with MPM by next generation sequencing |
I. Schmitt-Opitz |
|
Krebsforschung Schweiz |
Mesoscape 001-pS6: Construction of a multi-institutional European tissue bank |
I. Schmitt-Opitz |
|
Swiss National Science Foundation |
Magnetic resonance imaging for the detection of chronic lung allograft rejection in mouse lung transplantation |
W. Jungraithmayr (Co-Applicant) |
|
Swiss National Science Foundation, Förderungsprofessuren |
Malignant Pleural Mesothelioma – an integral approach for better outcome |
I. Schmitt-Opitz |
|
Forschungskredit der Universität Zürich |
Attenuation of acute lung allograft rejection by CD26 inhibition – a preclinical model |
W. Jungraithmayr |
|
Stiftung für wissenschaftliche Forschung, Zürich |
Lung tumor growth reduction by CD26 inhibition |
W. Jungraithmayr |
|
Assistenz-Professur an der UZH |
Lungentransplantation |
W. Jungraithmayr |
|
Förderungsprogramm „Filling the Gap“, FTG-1617-02 |
Attenuation of acute lung allograft rejection by CD26 inhibition – a preclinical model |
W. Jungraithmayr |
|
Hermann Klaus-Stiftung |
Primary lung tumor growth inhibition by CD26 |
W. Jungraithmayr |
|
Innovationspool |
Assessment and reconditioning of donor lungs with ex vivo lung perfusion system |
I. Inci |
|
Lungenliga Zürich |
Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia |
I. Inci |
|
Hermann-Klaus Stiftung |
Ex vivo reconditioning of donor lungs with Trimetazidine after prolonged cold ischemia |
I. Inci |
|
Hermann-Klaus Stiftung |
Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia |
I. Inci |
|
Hartmann-Müller Stiftung, Zürich |
The role of cytokine filtration during ex vivo lung perfusion |
I. Inci |
|
Lunge Zürich |
MicroRNAs as prognostic and predictive tumor markers assisting the selection of patients with Malignant Pleural Mesothelioma for multimoda-lity treat-ment |
I. Schmitt-Opitz, M. Kirschner |
|
Dr. Arnold U. u. Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung (Krebsstiftung) |
In vivo study of the efficacy of a dual phosphatidylinositol-3-kinase (PI3K)-/mTOR-inhibitor in the treatment of malignant pleural mesothelioma |
W. Weder, I. Schmitt-Opitz |
|
Krebsliga Zürich |
Prognostic Marker for Malignant Pleural Mesothelioma |
I. Schmitt-Opitz |
|
BECON AG Foundation |
Prognostische Marker für das Maligne Pleuramesotheliom |
I. Schmitt-Opitz |
|
Vontobel Stiftung |
MikroRNAs als prognostische und prädikative Tumormarker für die multimodale Behand-lung des malignen Pleura-mesothelioms |
I. Schmitt-Opitz, M. Kirschner |
|
Stiftung für angewandte Krebsforschung |
Activity based protein profiling in human lung cancer biopsies |
W. Weder, S. Hillinger, S. Arni |
|
Novartis Pharma AG Basel
|
Identification and validation of drug targets and biomarkers for COPD/emphysema and other end-stage lung disease |
W. Weder, S. Hillinger |
|
EMDO-Stiftung, Switzerland |
Impact of sevoflurane anesthesia on primary graft dysfunction after experimental mouse lung transplantation |
W. Jungraithmayr |
|
Universität Zürich, Projektförderung (Abt.I-III) |
Suppression of lung tumor growth by CD26/DPP4-inhibition |
W. Jungraithmayr |
|
Kurt und Senta Herrmann-Stiftung, Liechtenstein, Vaduz |
Blockade of CD26/DPP4-costimulation to improve lung transplant survival |
W. Jungraithmayr |
|
Helene Bieber-Fonds |
The CD26-costimlatory pathway is critical for Th17-mediated lung transplant improvement |
W. Jungraithmayr |
|
Quelle |
Projekttitel |
Projektleiter |
|
Matching Fund UZH 2012
|
Preclinical investigation of the role of hedgehog signaling on mesothelioma recurrence
|
I.Schmitt-Opitz
|
|---|---|---|
|
Matching Fund UZH 2011
|
Prognostic Marker for Malignant Pleural Mesothelioma
|
I.Schmitt-Opitz
|
|
Krebsliga Zürich
|
Prognistic Marker for Malignant Pleural Mesothelioma
|
I.Schmitt-Opitz
|
|
BECON AG Foundation
|
Prognostische Marker für das maligne Pleuramesotheliom
|
I.Schmitt-Opitz
|
|
Vontobel Stiftung
|
MikroRNAs als prognostische und pädikative Tumormarker für die multimodale Behandlung des malignen Pleuramesothelioms
|
I.Schmitt-Opitz
|
|
Krebsliga Zürich
|
Activity based protein profiling in human lung cancer biopsies
|
W.Weder,S.Hillinger, S.Arni
|
|
Novartis Pharma AG, Basel
|
Identification and validation of drug targets and biomarkers for COPD/emphysema and other end-stage lung disease
|
W.Weder, S.Hillinger
|
|
Matching Fund UZH 2012
|
Improvement of ischemia-reperfusion injury in murine lung transplatns by regenerative stern cells via inhibition of CD26/DPPIV
|
W.Jungraithmayr
|
|
EMDO-Stiftung 2013, Zurich
|
Impact of sevoflurane anesthesia on primary graft dysfunction after experimental mouse lung transplantation
|
W.Jungraithmayr
|
|
Universität Zürich, Projektförderung (Abt.I-III)
|
Suppression of lung tumor growth by CD26/DPP4-Inhibition
|
W.Jungraithmayr
|
|
Hermann-Klaus Stiftung, Zürich
|
Ex vivo reconditioning of donor lungs with Trimetazidine after prolonged cold ischemia
|
I.Inci
|
|
Hartmann-Müller Stiftung, Zürich |
Ex vivo reconditioning of donor lungs with inhaled N-Aceteyl cysteine after prolonged cold ischemia
|
I.Inci
|
| Quelle | Projektitel | Projektleiter |
|---|---|---|
|
Swiss National Science Foundation
|
Immunotherapy for lung cancer
|
S. Hillinger
|
|
Swiss National Science Foundation
|
The role of CD26/DPP IV and SDF-1 in pulmonary ischemic injury in a mouse
|
W. Jungraithmayr
|
|
Swiss National Science Foundation
|
Micro Computer-Tomographie für in-vivo Bildgebung
|
W. Jungraithmayr
(Co-Applicant) Applicant: PD Dr. A. Boss |
|
Hartmann-Müller Stiftung Zürich – 2012
|
Improvement of ischemia-reperfusion injury in muring lung transplants by stem cells via inhibition of DPP4 (Ges-Nr: 1591)
|
W. Jungraithmayr
|
|
Lungenliga Zürich
|
Rekonditionierung durch Magensäure geschädigter Lungentransplantate
Nicht-Herz-schlagenden Spendern |
I. Inci
|
|
Innovationspool
|
Assessment and recondi-tioning of donor lungs with ex vivo lung perfusion system
|
I.Inci
|
|
Lungenliga, Zürich
|
Ex vivo reconditioning of donor lungs with inhaled N-Acetyl cysteine after prolonged cold ischemia
|
I.Inci
|
|
Swiss National Science Foundation
|
In-Vivo Bioreactor for the reepithelialization of tissue engineered trachea
|
W.Weder
|
|
Dr. Arnold U. u. Susanne Huggenberger-Bischoff Stiftung zur Krebsforschung
(Krebsstiftung) |
In vivo study of the efficacy of a dual phosphatidylino-sitol-3-kinase (PI3K)-/mTOR-inhibitor in the treatment of malignant pleural mesothelioma
|
W. Weder, I. Schmitt-Opitz
|
|
BECON AG Foundation
|
Prognostische Marker für das Maligne Pleuramesotheliom
|
W. Weder, I. Schmitt-Opitz
|
|
Matching Fund UZH 2011
|
Malignant Pleural Mesothelioma – an integral approach for better outcome
|
I. Schmitt-Opitz
|
|
Matching Fund UZH 2012
|
Preclinical investigation of the role of hedgehog signaling on
mesothelioma recurrence |
I. Schmitt-Opitz
|
|
Matching Fund UZH 2011
|
Prognostic Marker for Malig-nant Pleural Mesothelioma
|
I. Schmitt-Opitz
|
|
Krebsliga Zürich
|
Prognostic Marker for Malig-nant Pleural Mesothelioma
|
I. Schmitt-Opitz
|
|
Swiss National Science Foundation
Förderungsprofessuren |
Malignant Pleural Mesothelioma – an integral approach for better outcome
|
I. Schmitt-Opitz
|
|
Krebsliga Zürich
|
Activity based protein profiling in human lung cancer biopsies
|
W. Weder, S. Hillinger,
S. Arni |
|
Novartis Pharma AG Basel
|
Identification and validation of drug targets and biomarkers for COPD/ emphysema and other end-stage lung disease
|
W. Weder, S. Hillinger
|
|
Matching Fund UZH 2012
|
Improvement of ischemia-reperfusion injury in murine lung transplants by regenerative stem cells via inhibition of CD26/DPPIV
|
W. Jungraithmayr
|
|
Matching Fund UZH 2011
|
Tolerance induction via NK cell mediated elimination of donor antigen presenting cells in mouse lung transplants
|
W. Jungraithmayr
|
|
EMDO-Stiftung 2013, Zurich, Switzerland
|
Impact of sevoflurane anesthesia on primary graft dysfunction after experimental mouse lung transplantation
|
W. Jungraithmayr
|
|
Quelle |
Projekttitel |
Projektleiter |
|
Hartmann-Müller Stiftung Zürich – 2012
|
Improvement of ischemia-reperfusion injury in muring lungtransplants by stem cells via inhibition of DPP4 (Ges-nr: 1591)
|
W. Jungraithmayr
|
|---|---|---|
|
Swiss National Science Foundation
Förderungsprofessuren |
Malignant Pleural Mesothelioma – an integral approach for
better outcome |
I. Schmitt-Opitz
|
|
Swiss National Science Foundation
|
The role of CD26/DPP IV and SDF-1 in pulmonary ischemic
injury in a mouse |
W. Jungraithmayr
|
|
Swiss National Science Foundation
|
Immune targeted therapy for lung cancer
|
S. Hillinger
|
|
Swiss National Science Foundation
|
In-Vivo Bioreactor for the reepithelialization of tissue engineered
trachea |
W. Weder
|
|
Swiss National Science Foundation
|
Micro Computer-Tomographie für in-vivo Bildgebung
|
W. Jungraithmayr (Co-
Applicant) Applicant: PD Dr. A. Boss |
|
Swiss National Science Foundation
|
Magnetic resonance imaging for the detection of chronic lung allograft rejection in mouse lung transplantation
|
W. Jungraithmayr (Co-
Applicant) Applicant: PD Dr. A. Boss |
|
Lungenliga Zürich
|
Rekonditionierung durch Magensäure geschädigter Lungentransplantate
Nicht-Herz-schlagenden Spendern |
I. Inci
|
|
Dr. Arnold U. u. Susanne Huggenberger-
Bischoff Stiftung zur Krebsforschung (Krebsstiftung) Co-applicant |
In vivo study of the efficacy of a dual phosphatidy-linositol-3-kinase (PI3K)-/mTOR-inhibitor in the treatment of malignant pleural mesothelioma
|
W. Weder, I. Schmitt-
Opitz |
|
Quelle |
Projekttitel |
Projektleiter |
|
Swiss National Science Foundation
|
Immune targeted therapy for lung cancer
|
S. Hillinger
|
|---|---|---|
|
Swiss National Science Foundation
|
NF In-Vivo Bioreactor for the reepithelialization of tissue engineered trachea
|
W.Weder
|
|
Swiss National Science Foundation
|
The role of CD26/DPP IV and SDF-1 in pulmonary ischemic injury in a mouse lung transplantation model
|
W. Jungraithmayr
|
|
Swiss National Science Foundation
|
Föderungsprofessur Isabelle Schmitt-Opitz
|
I. Schmitt-Opitz
|
|
Covidien Inc
|
Covidien LUN-06-002
|
W. Weder
|
|
Krebsliga Zürich
|
Adjuvante intrapleurale Spüllösung nach Pleuropneumonektomie nach malignen Pleuramesotheliom
|
I. Schmitt-Opitz
|
|
F. Hoffmann-La Roche Ltd., Bern
|
ETOP Lungscape Database collaboration between ETOP and Chinese
investigators |
W. Weder
|
|
Lungen Liga
|
Lungenliga Ex vivo evaluation and resuscitation of human donor lungs rejected for transplantation
|
W. Weder
|
|
ETOP European Thoracic Oncology Platform
|
ETOP Lungscape
|
W. Weder
|
|
Krebsliga Zürich
|
Activity based protein profiling in human lung cancer biopsies
|
W. Weder
|
| Quelle | Projekttitel | Projektleiter |
|---|---|---|
|
Swiss National Science Foundation
|
Immune targeted therapy for lung cancer
|
S. Hillinger
|
|
Swiss National Science Foundation
|
Trachea reconstruction using novel tissue
engineered constructs |
W. Weder
|
|
Swiss National Science Foundation
|
The role of CD26/DPP IV and SDF-1 in pulmonary
ischemic injury in a mouse lung transplantation model |
W. Jungraithmayr
|
|
Krebsliga Zürich
|
Prognostic markers for malignant pleural mesothelioma
|
I. Schmitt-Opitz
|
|
Krebsliga Zürich
|
Establishment of an integrated tumor tissue platform
and its application for comprehensive analyses of molecular parameters in lung tumors |
W. Weder
|
|
Krebsliga Zürich
|
Adjuvante intrapleurale Spüllösung nach Pleuropneumo-
nektomie beim malignen Pleuramesotheliom |
I. Schmitt-Opitz |
|
Fellowship European Society of Medical Oncology
|
Intrapleural therapy after surgery for malignant pleural
mesothelioma |
I. Schmitt-Opitz
|
|
Lungen Liga
|
Attenuation of ischemia-reperfusion injury by N-Acetylcysteine
after lung transplantation |
I.Inci
|
|
Lungen Liga
|
Reconditioning of category 3 non-heart beating donor
lungs insulted to gastric aspiration: Utilization of ex vivo lung perfusion system |
I.Inci
|
|
Dr. U. Arnold and Susanne Huggenberger-Bischoff Stiftung
zur Krebsforschung |
„Activity based protein profiling in human lung cancer biopsies
|
S. Arni
|
|
Krebsliga Zürich
|
Preclinical pharmacocinetic study for evaluation oif intrapleural
treatment with Cisplatin-fibrin after pneumonectomy for malig- nant pleural mesothelioma |
I. Schmitt-Opitz
|
|
Becon AG
|
Prognostische Marker für das maligne Pleura-mesothelioma
|
I. Schmitt-Opitz, W. Weder
|
|
Matching Fund
|
Prognostic Marker for Malignant Pleural Meso-thelioma
|
I. Schmitt-Opitz
|
|
Matching Fund
|
Activity based protein profiling in human lung cancer biopsies
|
W. Weder
|
|
Krebsliga Zürich
|
Activity based protein profiling in human lung cance biopsies
|
S. Arni
|